GTx-027

Experimental selective estrogen receptor modulator

GTx-027
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

GTx-027, also known as enobosarm, is an investigational selective estrogen receptor modulator (SERM) that is being developed for the treatment of conditions such as breast cancer and muscle wasting. It is a non-steroidal compound that exhibits tissue-selective activity, aiming to provide the beneficial effects of estrogens in certain tissues while avoiding undesirable effects in others.

Mechanism of Action

GTx-027 functions by binding to the estrogen receptors in a tissue-selective manner. This selective binding allows it to act as an agonist in some tissues, such as bone and muscle, while acting as an antagonist in others, such as breast tissue. This dual action is what makes GTx-027 a promising candidate for treating conditions like breast cancer, where estrogen can promote tumor growth, and muscle wasting, where estrogenic activity can be beneficial.

Clinical Development

GTx-027 has been the subject of various clinical trials to evaluate its efficacy and safety. It has shown potential in increasing lean body mass and improving physical function in patients with muscle wasting conditions. Additionally, its role in breast cancer treatment is being explored, particularly in cases where traditional estrogen receptor antagonists may not be suitable.

Potential Applications

The primary applications of GTx-027 include:

• Breast Cancer Treatment: As a SERM, GTx-027 may inhibit the growth of estrogen receptor-positive breast cancer cells by blocking estrogen's effects in breast tissue.
• Muscle Wasting Disorders: It may help in increasing muscle mass and strength in patients suffering from muscle wasting due to various conditions, including cancer cachexia and sarcopenia.

Safety and Side Effects

The safety profile of GTx-027 is still under investigation. Common side effects observed in clinical trials include hot flashes, nausea, and fatigue. As with any investigational drug, long-term safety data is required to fully understand its risk-benefit profile.

Related Pages

• Selective estrogen receptor modulator
• Breast cancer
• Muscle wasting
• Estrogen receptor